Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Schrijvers, M. Kars, M. Zande, M. Peters, M. Schuurmans, K. Fischer (2015)
Unravelling adherence to prophylaxis in haemophilia: a patients’ perspectiveHaemophilia, 21
A. Tiede, B. Brand, R. Fischer, K. Kavaklı, S. Lentz, T. Matsushita, C. Rea, K. Knobe, D. Viuff (2013)
Enhancing the pharmacokinetic properties of recombinant factor VIII: first‐in‐human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia AJournal of Thrombosis and Haemostasis, 11
Jonghan Kim, W. Hayton, J. Robinson, C. Anderson (2007)
Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model.Clinical immunology, 122 2
S. Björkman, Peter Collins (2013)
Measurement of factor VIII pharmacokinetics in routine clinical practiceJournal of Thrombosis and Haemostasis, 11
S. Bjorkman, A. Folkesson, E. Berntorp (2007)
In vivo recovery of factor VIII and factor IX: intra‐ and interindividual variance in a clinical settingHaemophilia, 13
L. Valentino, L. Rusen, I. Elezović, L. Smith, J. Korth-Bradley, P. Rendo (2014)
Multicentre, randomized, open‐label study of on‐demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjectsHaemophilia, 20
R. Peters, S. Low, George Kamphaus, J. Dumont, J. Amari, Qi Lu, Gregory Zarbis-Papastoitsis, Tom Reidy, E. Merricks, T. Nichols, A. Bitonti (2010)
Prolonged activity of factor IX as a monomeric Fc fusion protein.Blood, 115 10
B. Brand, R. Gruppo, Tung Wynn, L. Griškevičius, M. Fernández, M. Chapman, T. Dvorak, B. Pavlova, B. Abbuehl (2016)
Efficacy and safety of pegylated full‐length recombinant factor VIII with extended half‐life for perioperative haemostasis in haemophilia A patientsHaemophilia, 22
P. Collins, G. Young, K. Knobe, F. Karim, P. Angchaisuksiri, C. Banner, T. Gürsel, J. Mahlangu, T. Matsushita, E. Mauser-Bunschoten, J. Oldenburg, C. Walsh, C. Négrier (2014)
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial.Blood, 124 26
C. Broderick, R. Herbert, J. Latimer, C. Barnes, J. Curtin, E. Mathieu, P. Monagle, S. Brown (2012)
Association between physical activity and risk of bleeding in children with hemophilia.JAMA, 308 14
Indira Warrier, Indira Warrier, K. Baird-Cox, Jeanne Lusher, Jeanne Lusher (1997)
Use of central venous catheters in children with haemophilia: one haemophilia treatment centre experienceHaemophilia, 3
P. Collins, S. Björkman, K. Fischer, V. Blanchette, Myungshin Oh, P. Schroth, S. Fritsch, K. Casey, G. Spotts, B. Ewenstein (2010)
Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimensJournal of Thrombosis and Haemostasis, 8
P. Turecek, S. Romeder-Finger, C. Apostol, A. Bauer, A. Crocker-Buqué, D. Burger, R. Schall, H. Gritsch (2016)
A world‐wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATEHaemophilia, 22
K. Kavaklı, L. Smith, K. Kuliczkowski, J. Korth-Bradley, Chur You, J. Fuiman, S. Zupancic-Salek, F. Karim, P. Rendo (2016)
Once‐weekly prophylactic treatment vs. on‐demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia BHaemophilia, 22
M. Morfini, E. Zanon (2016)
Emerging drugs for the treatment of hemophilia A and BExpert Opinion on Emerging Drugs, 21
B. Mei, C. Pan, Haiyan Jiang, H. Tjandra, Jonathan Strauss, Yaoqi Chen, Tongyao Liu, Xin Zhang, J. Severs, J. Newgren, Jianmin Chen, Jian-Ming Gu, B. Subramanyam, M. Fournel, G. Pierce, John Murphy (2010)
Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment.Blood, 116 2
M. Ezban, K. Vad, M. Kjalke (2014)
Turoctocog alfa (NovoEight®) – from design to clinical proof of conceptEuropean Journal of Haematology, 93
T. Lissitchkov, M. Matysiak, K. Zavilska, P. Laguna, L. Gercheva, A. Antonov, A. Moret, P. Caunedo, J. Aznar, M. Woodward, A. Páez (2013)
Head‐to‐head comparison of the pharmacokinetic profiles of a high‐purity factor IX concentrate (AlphaNine®) and a recombinant factor IX (BeneFIX®) in patients with severe haemophilia BHaemophilia, 19
I. Bjørnsdottir, Ola Sternebring, Wendela Kappers, Helle Selvig, H. Kornø, J. Kristensen, M. Bagger (2016)
Pharmacokinetics, tissue distribution and excretion of 40kDa PEG and PEGylated rFVIII (N8-GP) in rats.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 87
R. Ljung, K. Fischer, M. Carcao, E. Santagostino, M. Manco‐Johnson, P. Mathew (2016)
Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levelsThrombosis and Haemostasis, 115
C. Négrier, K. Knobe, A. Tiede, P. Giangrande, J. Møss (2011)
Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B.Blood, 118 10
J. Powell, K. Pasi, M. Ragni, M. Ozelo, L. Valentino, J. Mahlangu, M. Med, N. Josephson, D. Perry, M. Manco‐Johnson, S. Apte, R. Baker, G. Chan, N. Novitzky, R. Wong, S. Krassova, G. Allen, Haiyan Jiang, A. Innes, Shuanglian Li, L. Cristiano, J. Goyal, J. Sommer, J. Dumont, Karen Nugent, G. Vigliani, Aoife Brennan, A. Luk, G. Pierce (2013)
Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.The New England journal of medicine, 369 24
I. Uijl, K. Fischer, J. Bom, D. Grobbee, F. Rosendaal, I. Plug (2011)
Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levelsHaemophilia, 17
U. Martinowitz, A. Shapiro, Doris Quon, Miguel Escobar, Christine Kempton, Peter Collins, P. Chowdary, Michael Makris, P. Mannucci, Massimo Morfini, Leonard Valentino, Edward Gomperts, Martin Lee (2012)
Pharmacokinetic properties of IB1001, an investigational recombinant factor IX, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysisHaemophilia, 18
M. Morfini (2003)
Pharmacokinetics of factor VIII and factor IXHaemophilia, 9
E. Santagostino, U. Martinowitz, T. Lissitchkov, B. Pan-Petesch, H. Hanabusa, J. Oldenburg, L. Boggio, C. Négrier, I. Pabinger, M. Prondzinski, C. Altisent, G. Castaman, Koji Yamamoto, M. Álvarez‐Román, Christine Voigt, N. Blackman, Iris Jacobs (2016)
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.Blood, 127 14
Massimo Morfini, Alfredo Dragani, E. Paladino, P. Radossi, G. Minno, M. Mazzucconi, G. Rossetti, Giovanni Barillari, Mariasanta Napolitano, G. Tagariello (2016)
Correlation between FIX genotype and pharmacokinetics of Nonacog alpha according to a multicentre Italian studyHaemophilia, 22
K. Fischer, E. Berntorp (2015)
Targeting Factor Replacement Therapy in Severe Hemophilia: Which Level Is Important?Seminars in Thrombosis & Hemostasis, 41
A. Gerrard, D. Austen, G. Brownlee (1992)
Subcutaneous injection of factor IX for the treatment of haemophilia BBritish Journal of Haematology, 81
J. Mahlangu, K. Kuliczkowski, F. Karim, O. Stasyshyn, M. Kosinova, L. Lepatan, A. Skotnicki, L. Boggio, R. Klamroth, J. Oldenburg, A. Hellmann, E. Santagostino, R. Baker, K. Fischer, J. Gill, S. P'Ng, P. Chowdary, M. Escobar, C. Khayat, L. Rusen, D. Bensen-Kennedy, N. Blackman, T. Limsakun, A. Veldman, K. Ledger, I. Pabinger (2016)
Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.Blood, 128 5
M. Shima, H. Hanabusa, M. Taki, T. Matsushita, Tetsuji Sato, K. Fukutake, Naoki Fukazawa, K. Yoneyama, Hiroki Yoshida, K. Nogami (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.The New England journal of medicine, 374 21
P. Turecek, M. Bossard, M. Graninger, H. Gritsch, W. Höllriegl, Martin Kaliwoda, Peter Matthiessen, Artur Mitterer, E. Muchitsch, M. Purtscher, H. Rottensteiner, A. Schiviz, G. Schrenk, Juergen Siekmann, K. Váradi, T. Riley, Hartmut Ehrlich, Hans Schwarz, F. Scheiflinger (2011)
BAX 855, a PEGylated rFVIII product with prolonged half-lifeHämostaseologie, 32
M. Carcao, A. Srivastava (2016)
Factor VIII/factor IX prophylaxis for severe hemophilia.Seminars in hematology, 53 1
J. Powell, N. Josephson, D. Quon, M. Ragni, G. Cheng, Ella Li, Haiyan Jiang, Lian Li, J. Dumont, J. Goyal, Xin Zhang, J. Sommer, J. Mccue, M. Barbetti, A. Luk, G. Pierce (2012)
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.Blood, 119 13
Stefan Schmidbauer, R. Witzel, L. Robbel, Petra Sebastian, N. Grammel, H. Metzner, S. Schulte (2015)
Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.Thrombosis research, 136 2
M. Witkop, J. McLaughlin, T. Anderson, J. Munn, A. Lambing, B. Tortella (2016)
Predictors of non‐adherence to prescribed prophylactic clotting‐factor treatment regimens among adolescent and young adults with a bleeding disorderHaemophilia, 22
R. Stidl, S. Fuchs, M. Bossard, J. Siekmann, P. Turecek, M. Putz (2015)
Safety of PEGylated recombinant human full‐length coagulation factor VIII (BAX 855) in the overall context of PEG and PEG conjugatesHaemophilia, 22
P. Chowdary, S. Lethagen, S. Lethagen, U. Friedrich, B. Brand, C. Hay, F. Karim, R. Klamroth, P. Knoebl, M. Laffan, J. Mahlangu, W. Miesbach, J. Nielsen, M. Martin-Salces, P. Angchaisuksiri (2015)
Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trialJournal of Thrombosis and Haemostasis, 13
P. Taupin (2011)
Chimeric proteins comprising the constant region of immunoglobulins for treating hemophilia B (WO2005001025)Expert Opinion on Therapeutic Patents, 21
T. Coyle, M. Reding, J. N, J. E, Coyle Te, Reding Mt, Jc Lin, Michaels La, Shah A, Powell Phase (2014)
Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia AJournal of Thrombosis and Haemostasis, 12
Peter Collins, Elizabeth Chalmers, P. Chowdary, David Keeling, M. Mathias, James O’Donnell, K. Pasi, Savita Rangarajan, Alun Thomas (2016)
The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDOHaemophilia, 22
K. Swiech, A. Kamen, S. Ansorge, Y. Durocher, V. Picanço-Castro, E. Russo-Carbolante, Mário Neto, D. Covas (2011)
Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIIIBMC Biotechnology, 11
Sang‐Hwan Oh, Mi-young Lee, D. Song (1999)
Synthesis of recombinant blood coagulation factor VIII (FVIII) heavy and light chains and reconstitution of active form of FVIIIExperimental & Molecular Medicine, 31
R. Klamroth, M. Simpson, M. Depka-prondzinski, Joan Gill, Massimo Morfini, Jerry Powell, Elena Santagostino, Joanna Davis, A. Huth‐Kühne, Cindy Leissinger, Peter Neumeister, D. Bensen-Kennedy, A. Feussner, T. Limsakun, M. Zhou, A. Veldman, K. Ledger, Nicole Blackman, Ingrid Pabinger (2016)
Comparative pharmacokinetics of rVIII‐SingleChain and octocog alfa (Advate®) in patients with severe haemophilia AHaemophilia, 22
Leonard Valentino, S. Pipe, P. Collins, Victor Blanchette, Erik Berntorp, Kathelijn Fischer, Bruce Ewenstein, Myungshin Oh, G. Spotts (2016)
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic‐guided prophylaxisHaemophilia, 22
C. Hay, B. Palmer, E. Chalmers, D. Hart, R. Liesner, S. Rangarajan, K. Talks, Michael Williams, P. Collins (2015)
The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full‐length to B‐domain‐deleted factor VIII: a prospective cohort comparisonHaemophilia, 21
F. Peyvandi, P. Mannucci, I. Garagiola, A. El‐Beshlawy, M. Elalfy, V. Ramanan, P. Eshghi, S. Hanagavadi, R. Varadarajan, M. Karimi, M. Manglani, C. Ross, G. Young, T. Seth, S. Apte, D. Nayak, E. Santagostino, M. Mancuso, Adriana Gonzalez, J. Mahlangu, Santiago Boix, M. Cerqueira, N. Ewing, C. Male, T. Owaidah, Veronica Arellano, N. Kobrinsky, S. Majumdar, R. Garrido, A. Sachdeva, M. Simpson, Mathew Thomas, E. Zanon, B. Antmen, K. Kavaklı, M. Manco‐Johnson, Monica Martinez, E. Marzouka, M. Mazzucconi, D. Neme, Á. Bravo, R. Aguilera, A. Prezotti, K. Schmitt, B. Wicklund, B. Zulfikar, F. Rosendaal (2016)
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.The New England journal of medicine, 374 21
José Aznar, N. Cabrera, M. Matysiak, Krystyna Zawilska, L. Gercheva, A. Antonov, M. Montanes, A. Páez, T. Lissitchkov (2009)
Pharmacokinetic study of a high‐purity factor IX concentrate (Factor IX Grifols®) with a 6‐month follow up in previously treated patients with severe haemophilia BHaemophilia, 15
S. Zollner, E. Raquet, J. Müller-Cohrs, H. Metzner, T. Weimer, I. Pragst, G. Dickneite, S. Schulte (2013)
Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.Thrombosis research, 132 2
K. Fischer, Peter Collins, M. Ozelo, A. Srivastava, G. Young, V. Blanchette (2016)
When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTHJournal of Thrombosis and Haemostasis, 14
M. Morfini (2006)
Pharmacokinetic studies: international guidelines for the conduct and interpretation of such studiesHaemophilia, 12
P. Giangrande, T. Andreeva, P. Chowdary, S. Ehrenforth, H. Hanabusa, F. Leebeek, S. Lentz, L. Nemes, L. Poulsen, E. Santagostino, Chur You, Wan Clausen, Peter Jönsson, J. Oldenburg (2016)
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia AThrombosis and Haemostasis, 117
E. Berntorp, N. Andersson (2016)
Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX ProductsSeminars in Thrombosis & Hemostasis, 42
A. Klukowska, Tomasz Szczepański, V. Vdovin, S. Knaub, M. Jansen, R. Liesner (2016)
Novel, human cell line‐derived recombinant factor VIII (Human‐cl rhFVIII, Nuwiq®) in children with severe haemophilia A: efficacy, safety and pharmacokineticsHaemophilia, 22
A. Haack, C. Schmitt, W. Poller, J. Oldenburg, P. Hanfland, H. Brackmann, R. Schwaab (1999)
Analysis of expression kinetics and activity of a new B-domain truncated and full-length FVIII protein in three different cell linesAnnals of Hematology, 78
Steven Lentz, M. Misgav, Margareth Ozelo, S. Šalek, D. Veljković, Michael Recht, M. Cerqueira, Andreas Tiede, B. Brand, M. Mancuso, Stephanie Seremetis, A. Lindblom, U. Martinowitz (2013)
Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacyHaemophilia, 19
(2012)
Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients.Blood, 120 12
L. Schrijvers, M. Schuurmans, Kathelijn Fischer (2016)
Promoting self‐management and adherence during prophylaxis: evidence‐based recommendations for haemophilia professionalsHaemophilia, 22
C. Chaudhury, C. Brooks, D. Carter, J. Robinson, C. Anderson (2006)
Albumin binding to FcRn: distinct from the FcRn-IgG interaction.Biochemistry, 45 15
P. Nielsen, S. Bak, B. Vandahl (2012)
Characterization of tyrosine sulphation in rFVIII (turoctocog alfa) expressed in CHO and HEK‐293 cellsHaemophilia, 18
H. Metzner, T. Weimer, U. Kronthaler, W. Lang, S. Schulte (2009)
Genetic fusion to albumin improves the pharmacokinetic properties of factor IXThrombosis and Haemostasis, 102
J. Mahlangu, J. Powell, M. Ragni, P. Chowdary, N. Josephson, I. Pabinger, H. Hanabusa, N. Gupta, R. Kulkarni, P. Fogarty, D. Perry, A. Shapiro, K. Pasi, S. Apte, I. Nestorov, Haiyan Jiang, Shuanglian Li, S. Neelakantan, L. Cristiano, J. Goyal, J. Sommer, J. Dumont, Nigel Dodd, Karen Nugent, G. Vigliani, A. Luk, Aoife Brennan, G. Pierce (2014)
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.Blood, 123 3
S. Schulte (2011)
Pioneering designs for recombinant coagulation factors.Thrombosis research, 128 Suppl 1
L. Schrijvers, M. Cnossen, M. Zande, M. Peters, M. Schuurmans, K. Fischer (2016)
Defining adherence to prophylaxis in haemophiliaHaemophilia, 22
B. Nolan, Johnny Mahlangu, David Perry, Guy Young, R. Liesner, Barbara Konkle, Savita Rangarajan, S. Brown, H. Hanabusa, K. Pasi, Ingrid Pabinger, Shannon Jackson, L. Cristiano, X. Li, G. Pierce, G. Allen (2016)
Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia AHaemophilia, 22
L. Schrijvers, M. Zande, M. Peters, J. Lock, M. Cnossen, M. Schuurmans, K. Fischer (2016)
Adherence to prophylaxis and bleeding outcome in haemophilia: a multicentre studyBritish Journal of Haematology, 174
S. Schulte (2009)
Half-life extension through albumin fusion technologies.Thrombosis research, 124 Suppl 2
S. Björkman, Victor Åhlén (2012)
Population pharmacokinetics of plasma-derived factor IX in adult patients with haemophilia B: implications for dosing in prophylaxisEuropean Journal of Clinical Pharmacology, 68
S. Björkman (2013)
Pharmacokinetics of plasma‐derived and recombinant factor IX – implications for prophylaxis and on‐demand therapyHaemophilia, 19
B. Konkle, O. Stasyshyn, P. Chowdary, D. Bevan, T. Mant, M. Shima, W. Engl, J. Dyck-Jones, Monika Fuerlinger, L. Patrone, B. Ewenstein, B. Abbuehl (2015)
Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.Blood, 126 9
H. Stass (2006)
Determination of minimal sampling time points for reliable pharmacokinetic evaluation of recombinant factor VIII – an exploratory population pharmacokinetic analysis in paediatric patients suffering from severe haemophiliaHaemophilia, 12
D. Matino, D. Lillicrap, J. Astermark, G. Dolan, C. Kessler, T. Lambert, M. Makris, J. O’Donnell, S. Pipe, E. Santagostino, J. Saint-Remy, W. Schramm, Alfonso Iorio (2014)
Switching clotting factor concentrates: considerations in estimating the risk of immunogenicityHaemophilia, 20
The improvement of clotting factor concentrates (CFCs) has undergone an impressive boost during the last six years. Since 2010, several new recombinant factor (rF)VIII/IX concentrates entered phase I/II/III clinical trials. The improvements are related to the culture of human embryonic kidney (HEK) cells, post-translational glycosylation, PEGylation, and co-expression of the fragment crystallizable (Fc) region of immunoglobulin (Ig)G1 or albumin genes in the manufacturing procedures. The extended half-life (EHL) CFCs allow an increase of the interval between bolus administrations during prophylaxis, a very important advantage for patients with difficulties in venous access. Although the inhibitor risk has not been fully established, phase III studies have provided standard prophylaxis protocols, which, compared with on-demand treatment, have achieved very low annualized bleeding rates (ABRs). The key pharmacokinetics (PK) parameter to tailor patient therapy is clearance, which is more reliable than the half-life of CFCs; the clearance considers the decay rate of the drug concentration–time profile, while the half-life considers only the half concentration of the drug at a given time. To tailor the prophylaxis of hemophilia patients in real-life, we propose two formulae (expressed in terms of the clearance, trough and dose interval between prophylaxis), respectively based on the one- and two-compartmental models (CMs), for the prediction of the optimal single dose of EHL CFCs. Once the data from the time decay of the CFCs are fitted by the one- or two-CMs after an individual PK analysis, such formulae provide to the treater the optimal trade-off among trough and time-intervals between boluses. In this way, a sufficiently long time-interval between bolus administration could be guaranteed for a wider class of patients, with a preassigned level of the trough. Finally, a PK approach using repeated dosing is discussed, and some examples with new EHL CFCs are shown.
Therapeutic Advances in Hematology – SAGE
Published: Jun 1, 2018
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.